Patent Evaluation: Novel isochroman calcium channel antagonists for the treatment of ischaemic heart disease

Summary

Novelty: A series of isochroman Ca²⁺ channel antagonists is disclosed. The compounds are potentially useful cerebral and cardiac anti-ischaemic agents and have potential anti-anginal and anti-arrhythmic activity.

Biology: No biological data are presented.

Chemistry: Synthesis of the compounds forms a subsidiary part of the claim, exemplified in fourteen cases. 1-[4,4-Bis(4-fiuorophenyl)butyl]-4-[(3,4-dihydro-6,7-dimethoxy-1H-2-benzopyran-1-yl)methyl]piperazine is one of two specifically claimed compounds.

Structure: